We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$407M
AUM Growth
-$38.3M
Cap. Flow
-$52.4M
Cap. Flow %
-12.88%
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$6.14M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$5.93M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.36M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.07M
5
ZYME icon
Zymeworks
ZYME
+$808K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.83M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.57M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.53M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$966K

Sector Composition

Rank Sector Weight
1 Industrials 19.96%
2 Technology 18%
3 Healthcare 15.75%
4 Materials 7.84%
5 Financials 7.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EMN icon
126
Eastman Chemical
EMN
$7.78B
$896K 0.22%
9,362
+104
+1% +$10.3K
ZYME icon
127
Zymeworks
ZYME
$1.75B
$887K 0.22%
+56,490
New +$808K
CMCSA icon
128
Comcast
CMCSA
$84.9B
$883K 0.22%
24,944
+29
+0.1% +$1.03K
SHY icon
129
iShares 1-3 Year Treasury Bond ETF
SHY
$25.4B
$881K 0.22%
10,604
+54
+0.5% +$4.49K
UPS icon
130
United Parcel Service
UPS
$96.2B
$873K 0.21%
7,477
+50
+0.7% +$5.88K
PSX icon
131
Phillips 66
PSX
$83.7B
$857K 0.21%
7,604
+63
+0.8% +$7.28K
ECL icon
132
Ecolab
ECL
$75.6B
$854K 0.21%
5,448
+84
+2% +$12.5K
PFBC icon
133
Preferred Bank
PFBC
$1.27B
$852K 0.21%
14,557
+775
+6% +$48.6K
TMHC icon
134
Taylor Morrison
TMHC
$6.66B
$838K 0.21%
46,475
-740
-2% -$14.7K
MTB icon
135
M&T Bank
MTB
$36.2B
$837K 0.21%
5,089
+25
+0.5% +$4.34K
CB icon
136
Chubb
CB
$137B
$836K 0.21%
6,257
+82
+1% +$11.1K
MRUS
137
DELISTED
Merus
MRUS
$835K 0.21%
42,321
-15,075
-26% -$320K
MAS icon
138
Masco
MAS
$15.6B
$819K 0.2%
22,387
-1,262
-5% -$48.5K
TRIL
139
DELISTED
Trillium Therapeutics Inc.
TRIL
$809K 0.2%
139,403
+2,312
+2% +$13K
ASIX icon
140
AdvanSix
ASIX
$551M
$795K 0.2%
23,421
+844
+4% +$30.3K
DFS
141
DELISTED
Discover Financial Services
DFS
$778K 0.19%
10,176
+346
+4% +$26.1K
IEFA icon
142
iShares Core MSCI EAFE ETF
IEFA
$185B
$777K 0.19%
12,124
-92
-0.8% -$5.87K
GPK icon
143
Graphic Packaging
GPK
$3.21B
$775K 0.19%
55,312
+1,352
+3% +$19.5K
ALNT icon
144
Allient
ALNT
$1.47B
$774K 0.19%
+21,342
New +$693K
HF
145
DELISTED
HFF Inc.
HF
$759K 0.19%
17,869
+399
+2% +$16.8K
RTEC
146
DELISTED
Rudolph Technologies Inc
RTEC
$756K 0.19%
30,921
+1,154
+4% +$31.8K
FORM icon
147
FormFactor
FORM
$8.21B
$754K 0.19%
+54,825
New +$756K
BCC icon
148
Boise Cascade
BCC
$2.67B
$743K 0.18%
20,190
+703
+4% +$30.6K
ALG icon
149
Alamo Group
ALG
$1.95B
$725K 0.18%
7,914
+184
+2% +$17.3K
HY icon
150
Hyster-Yale Materials Handling
HY
$569M
$711K 0.17%
11,549
+460
+4% +$29.1K
4 5
6
7 8

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q3 2018 Portfolio in Review

As of Q3 2018, Stanley-Laman Group held 282 positions worth $407M, down 8.6% from $445M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Stanley-Laman Group withdrew a net $52.4M in Q3 2018, closing 63 positions and reducing 110 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $8.83M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stanley-Laman Group opened a new position in Acceleron Pharma worth $7.16M.

  • Stanley-Laman Group's largest Q3 2018 buy was Acceleron Pharma: 125,020 shares worth $7.16M.
  • Stanley-Laman Group added most to Prudential Financial in Q3 2018, an estimated $152K increase.
  • Stanley-Laman Group's biggest Q3 2018 reduction was Hortonworks, Inc., cutting an estimated $629K.
  • Stanley-Laman Group fully exited Neurocrine Biosciences in Q3 2018, selling an estimated $8.83M.
  • Stanley-Laman Group's ten largest holdings make up 19% of its $407M portfolio in Q3 2018.
  • Stanley-Laman Group opened 19 new positions and closed 63 in Q3 2018.
  • Stanley-Laman Group's portfolio value fell 8.6% quarter-over-quarter to $407M.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.